Kyverna Therapeutics (KYTX) said late Tuesday it appointed Naji Gehchan as chief medical and development officer.
Gehchan most recently served as the head of clinical development for the imlunestrant breast cancer treatment at Eli Lilly (LLY).
Shares of Kyverna Therapeutics were up 3% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.